Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — FY2020 Earnings Presentation
22 slides from Vivoryon Therapeutics's earnings presentation, Apr 30, 2021
Slide 1: 2020 Full Year Results & Outlook 2021
2020 FULL YEAR RESULTS & OUTLOOK 2021 Halle (Saale)/Munich, April 30, 2021 | Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on,
Slide 3: Welcome to Vivoryon Therapeutics
WELCOME TO VIVORYON THERAPEUTICS - on the call today - Dr. Ulrich Dauer Florian Schmid Dr. Michael Schaeffer Chief Executive Officer Chief Financial Officer Chief Business Officer © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 3
Slide 4: Agenda
01 HIGHLIGHTS IN 2020 02 R&D UPDATE AND OUTLOOK AGENDA 03 CORPORATE UPDATE AND OUTLOOK 04 FINANCIALS 2020 05 CLOSING REMARKS 06 Q&A © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021
Slide 5: Highlights in 2020
01 HIGHLIGHTS IN 2020
Slide 6: Highlights 2020
HIGHLIGHTS 2020 Highlights § Start of development program for meprin protease inhibitors with intended therapeutic use in fibrosis and cancer § Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer’s Disease Study with Varoglutamstat § Receive of FDA’s IND approval for varoglutamstat‘s
Slide 7: R&D Update and Outlook
02 R&D UPDATE AND OUTLOOK
Slide 8: Substantial Pipeline Progress
SUBSTANTIAL PIPELINE PROGRESS © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 8
Slide 9: Varoglutamstat (PQ912) in Clinical Phase 2
VAROGLUTAMSTAT (PQ912) IN CLINICAL PHASE 2 A Phase 2b Multicentre, Randomized, A Phase 2a Randomized Double-Blind Double-blind, Placebo-controlled, Placebo-controlled Trial to Evaluate the Parallel Group Dose Finding, Safety, Efficacy and Safety of Varoglutamstat Targeting N3pG: Tolerability and Eff
Slide 10: QPCTL Inhibitors in Oncology: Dual MoA
QPCTL INHIBITORS IN ONCOLOGY: DUAL MoA § Targeting the CD47-SIRPa innate immune system § First-in-class approach to destabilize and deactivate checkpoint. First-in-class small molecule approach, to the tumorigenic and pro-inflammatory chemokine boost anti tumor antibody therapies CCL2. §. § Extended
Slide 11: Meprin: A Novel Fibrosis Target
MEPRIN: A NOVEL FIBROSIS TARGET § Protease critical for collagen re-modelling and for the activation of inflammatory cytokines (IL-1, IL6…) § Target indications: AKI, CKD, Fibrosis and Cancer § Animal proof-of-concept in AKI model § Portfolio of nanomolar inhibitors selective for Meprin a and b or b
Slide 12: Corporate Update and Outlook
03 CORPORATE UPDATE AND OUTLOOK
Slide 13: Conversion of Vivoryon into an N.V. Successfully Completed
CONVERSION OF VIVORYON INTO AN N.V. SUCCESSFULLY COMPLETED N.V. Rationale for the conversion of Vivoryon’s legal form: § Increasing competitiveness in - Fulfillment of capital market requirements AG - Expansion of strategic options - Exploitation of favorable market conditions - Attraction of intern
Slide 14: Shareholders and Stock
SHAREHOLDERS AND STOCK Shareholder structure1 Stock Share Price ISIN: NL00150002Q7 WKN: A2QJV6 Ticker symbol: VVY Types of shares: Bearer shares Number of shares 19,975,482 Euronext Amsterdam Stock exchange: XETRA, Frankfurt Liquidity provider: Kempen & Co. Listing agent: Kempen & Co. First trading
Slide 15: Financials 2020
04 FINANCIALS 2020
Slide 16: Key Financial Highlights (P&L): According to IFRS
KEY FINANCIAL HIGHLIGHTS (P&L): ACCORDING TO IFRS IN €k 2020 2019 % Research and development expenses (13,210) (4,789) 175.8 General and administrative expenses (2,807) (3,062) (8.3) Other operating income 6 59 (89,8) Operating loss (16,510) (7,823) 105.5 Finance income 105 0 Finance expenses (604)
Slide 17: Key Financial Figures (According to IFRS)
KEY FINANCIAL FIGURES (ACCORDING TO IFRS) In €k Dec 31, 2020 Dec 31, 2019 Earnings, Financial and Net Assets Position Operating loss (16,011) (7,792) Finance result (499) (31) Net loss for the period (16,510) (7,823) Total equity 26,221 42,665 Equity ratio (end of the year) (in %) 88.1% 93.0 % Balan
Slide 18: Closing Remarks
05 CLOSING REMARKS
Slide 19: Financial Calendar 2021
FINANCIAL CALENDAR 2021 June 01, 2021 Interim Management Statement Q1 2021 June 28, 2021 Annual General Meeting 2021 September 21, 2021 Interim Report, Half Year Results 2021 November 23, 2021 Interim Management Statement Q3 2021 © Vivoryon Therapeutics N.V. FY 2020 – April 30, 2021 Please note: Sub
Slide 20: Q&A
06 Q&A
Slide 21: www.vivoryon.com
www.vivoryon.com Halle (Saale) Munich Weinbergweg 22 Franz-Josef-Delonge-Str. 5 06120 Halle (Saale) 81249 München Germany Germany [email protected] +49 (0)345 555 99 00
Slide 22: Appendix
APPENDIX